A Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing Haemodialysis
Latest Information Update: 17 Jun 2014
At a glance
- Drugs Paricalcitol (Primary)
- Indications Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Abbott Laboratories
Most Recent Events
- 17 Jun 2014 New trial record